Evaluation of Non-B Non-C Liver Cirrhosis in A EL-Rajhi Assuit University Hospital: A Retrospective-Prospective Study

A

Assiut University

Status

Not yet enrolling

Conditions

Non-B Non-C Liver Cirrhosis

Treatments

Diagnostic Test: Diagnostic tests

Study type

Observational

Funder types

Other

Identifiers

NCT05314270
Non-B Non-C Liver cirrhosis

Details and patient eligibility

About

To study the etiologies of patients diagnosed as non-B, non-C liver cirrhosis (NBNC-LC). To describe the different patient's outcomes.

Full description

Liver cirrhosis is the ultimate fate of many hepatic insults that may be viral, immunologic, and metabolic or even cryptogenic. (Tsochatzis EA et al., 2014) Recently, Non-Alcoholic Fatty Liver Disease (NAFLD) present a serious health burden worldwide that affects around 25% of the global adult population with a prevalence of around 31.8% in the Middle East. (Younossi ZM, et al., 2019) Most of Egyptian patients presented with end-stage liver disease are secondary to post-hepatitic cirrhosis is estimated to be more than 80% of cases. (Guerra J et al., 2012) The real profile of non-B, non-C etiologies of liver cirrhosis, in Egyptian patients, is still not fully evaluated.

Enrollment

100 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • All pateints diagnosed as Non-B Non-C Liver Cirrhosis in the period from 2017_2023

Exclusion criteria

  • We will exclude the pateints that will be diagnosed as HBV-HCV induced Liver Cirrosis

Trial contacts and locations

0

Loading...

Central trial contact

Magda Shehata Hassan; Abdelrahman Mohammed Abdelrahman Morsi

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems